medRxiv preprint doi: https://doi.org/10.1101/2022.10.16.22281137; this version posted October 17, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Title Page

Running Title: Serological Cross-reactivity in Rickettsiae

Keywords: Cross-reactions; Antigen-antibody reactions; Immunoenzyme Techniques; Murine Typhus; Rickettsia typhi; Typhus, Endemic Flea-Borne; Japanese Spotted Fever; Rickettsia japonica; Spotted Fever Group Rickettsiosis; Rickettsia

Title

Serological Cross-Reactivity Between Spotted Fever and Typhus Groups of Rickettsia Infection in Japan

Authors:

Tetsuro Aita, Eiichiro Sando, Shungo Katoh, Sugihiro Hamaguchi, Hiromi Fujita[1], Noriaki Kurita

[1] Deceased.

Author Affiliations:

Fukushima Medical University, Fukushima, Japan (T.Aita, E.Sando, S.Katoh, H.Sugihiro, N.Kurita)

Kita-Fukushima Medical Center, Fukushima, Japan (E. Sando, S. Katoh, H. Fujita)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2022.10.16.22281137; this version posted October 17, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Ethics:

The study was approved by Institutional Review Board at Fukushima Medical University.

Corresponding author:

Eiichiro Sando, MD, PhD, FACP

Department of General Internal Medicine and Clinical Infectious Diseases, Fukushima Medical University, Fukushima, Japan

Department of General Internal Medicine and Infectious Diseases, Kita-Fukushima Medical Center, Fukushima, Japan

Mailing address: 1 Hikarigaoka, Fukushima city, Fukushima, 960-1295, Japan

Email address: e-sando@fmu.ac.jp

Phone number: +81-24-547-1933

Fax number: +81-24-547-1210

medRxiv preprint doi: https://doi.org/10.1101/2022.10.16.22281137; this version posted October 17, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Abstract 47/50 words

We examined the frequency of cross-reactions to *Rickettsia typhi* in patients with Japanese spotted fever and found that approximately 20% of cases were positive. Comparison of antibody titers revealed the difficulty in identifying some positive cases. The frequency of misclassification in serodiagnosis was found to be limited.

Text—word count 780/800

【Introduction】

Conventional serodiagnosis using indirect immunofluorescence assay (IFA) or indirect immunoperoxidase assay (IP) in paired sera remains a cornerstone for acute infections of two antigenic groups of the genus *Rickettsia*: the spotted fever group (SFG) and typhus group (TG) (1). However, serological cross-reactions between different groups can occur and cause misclassification during serodiagnosis, leading to misdiagnosis, especially in patients with non-specific clinical features (1). The cross-reactivity within SFG was previously investigated (2), whereas that between SFG and TG is yet to be fully evaluated. Uchiyama et al. identified cross-reactive antibodies of *Rickettsia typhi*, a TG rickettsia causing murine typhus (MT), with those of *Rickettsia japonica*, an SFG rickettsia causing Japanese spotted fever (JSF), in patients with JSF using western immunoblotting and cross-absorption (3). However, these assays are difficult to implement as standard diagnostic tests because they require expertise. Clinicians must speculate on cross-reactions based on clinical features and conventional serological results in paired sera. Although experts have proposed that the variation of each rickettsial antibody titer in two phases differentiates a true infection from a cross-reaction (4), no clinical evidence is available to support this. Therefore, using a conventional method, we aimed to investigate the cross-reactions

medRxiv preprint doi: https://doi.org/10.1101/2022.10.16.22281137; this version posted October 17, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

between *R. japonica* and *R. typhi* in paired sera from patients with clinically and serologically confirmed *R. japonica* infections.

【Methods】

We retrospectively examined serological data from two reference centers for rickettsiosis in Japan between January 1, 2003, and December 31, 2016. All patient samples were tested by IP using the Aoki strain of *R. japonica* and the Wilmington strain of *R. typhi* (Appendix). In the present study, patients with JSF were defined as having clinical features of the disease and a ≥4-fold increase in IgM or IgG titers against *R. japonica* or seroconverted (defined as titers ≥80) in paired sera (5).

The cross-reaction was defined as a higher titer against *R. typhi* in convalescent sera than that in acute sera (2), and its frequency was evaluated for IgM and IgG. We also investigated the presence of cross-reactivity in patients diagnosed with JSF using polymerase chain reaction (PCR) or immunohistochemistry in skin biopsy specimens (6). Additionally, the patient samples that indicated cross-reactivity but posed challenges in being identified as either JSF or MT based on IP alone, were subjected to indirect hemagglutination tests (HA) (7,8).

【Results】

A total of 145 patients diagnosed with JSF were analyzed. The median interval between acute and convalescent serum collection was 13 (interquartile range, 8–17) days. The changes in titers for *R. japonica* and *R. typhi* are indicated in the Appendix Figure. The cross-reactions against *R. typhi* in patients with JSF were observed in 21.4% of cases (27/126, 95% confidence

medRxiv preprint doi: https://doi.org/10.1101/2022.10.16.22281137; this version posted October 17, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

interval [CI] 14.6–29.6) for IgM and 19.6% (27/138, 95% CI 13.3–27.2) for IgG (Figure). IgM and IgG titers are indicated in Appendix Table 1 and Table, respectively. Additionally, in 11 cases of JSF that were confirmed using PCR or immunohistological tests, cross-reactions were observed in 18.2% of cases (2/11, 95% CI 2.3–51.8) each for IgM and IgG, with the titers listed in Appendix Table 2. Eight cases could not be identified as true infections or cross-reactions by comparing endpoint titer levels of two rickettsiae; seven cases of these could be differentiated using HA (Appendix Tables 3 and 4).

【Discussion】

In this study, using conventional serological methods in paired sera, we identified that the proportion of cross-reactions between *R. japonica* and *R. typhi* in patients with JSF was approximately 20%, suggesting a limited possibility of misclassification in serodiagnosis. The robustness of our results was supported by a similar frequency of cross-reactions in patients with JSF that was confirmed using PCR or immunohistological skin findings.

To our knowledge, only one study has investigated the serological cross-reactions between JSF and MT. A previous study identified cross-reactions between *R. japonica* and *R. typhi* in patients with JSF using IFA, immunoblotting, and cross-adsorption assays, focusing on the identification of proteins with common antigenicity using a small sample size (3). Thus, our study is the first to estimate the frequency of cross-reactions using a large number of patients with JSF and evaluate distinguishability using changes in antibody titers.

The value of endpoint antibody titers was proposed to differentiate SFG from TG (2,4,9), but this remains controversial. In fact, using a case definition of clinically and serologically

medRxiv preprint doi: https://doi.org/10.1101/2022.10.16.22281137; this version posted October 17, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

confirmed (IP) patients with JSF, some patients with JSF with cross-reactions had high endpoint titers of *R. typhi*.

Especially in cases with non-specific rickettsial symptoms, the cross-reaction results in our study may provide other possibilities: co-infection with *R. japonica* and *R. typhi*, cross-reactions against *R. typhi* in patients with *R. japonica* infection and previous *R. typhi* infection, or even cross-reactions against *R. japonica* in patients with true *R. typhi* infection.

Acknowledgments

This work was supported by JSPS KAKENHI (Grant Number JP 19K23972) and AMED (Grant Number JP21fk0108614).

Author Bio

T. Aita is an internist specializing in general internal medicine and clinical epidemiology. He is affiliated with the Department of General Internal Medicine, Fukushima Medical University as a teaching/research associate and is interested in research on the epidemiology of diseases, diagnostic accuracy, and infections, such as rickettsia.

References

1. Robinson MT, Satjanadumrong J, Hughes T, Stenos J, Blacksell SD. Diagnosis of spotted fever group Rickettsia infections: Asian perspective. Epidemiol Infect. 2019 7 Oct;147:e286.

medRxiv preprint doi: https://doi.org/10.1101/2022.10.16.22281137; this version posted October 17, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

2. Vaughn MF, Delisle J, Johnson J, Daves G, Williams C, Reber J, et al. Seroepidemiologic study of human infections with spotted fever group Rickettsiae in North Carolina. J Clin Microbiol. 2014 Nov;52(11):3960–6.

3. Uchiyama T, Zhao L, Yan Y, Uchida T. Cross-reactivity of Rickettsia japonica and Rickettsia typhi demonstrated using immunofluorescence and western immunoblotting. Microbiol Immunol. 1995;39(12):951–7.

4. Hechemy KE, Raoult D, Fox J, Han Y, et al.: Cross-reaction of immune sera from patients with rickettsial diseases. J Med Microbiol. 1989 Jul;29(3):199–202.

5. Sando E, Ariyoshi K, Fujita H. Serological cross-reactivity among Orientia tsutsugamushi serotypes, but not with Rickettsia japonica in Japan. Trop Med Infect Dis. 2018;3(3):74.

6. Tamakuma K, Mizutani Y, Ito M, Shiogama K, Inada K, Miyamoto K, et al. Histopathological diagnosis of Japanese spotted fever using formalin-fixed, paraffin-embedded skin biopsy specimens: Usefulness of immunohistochemistry and real-time PCR analysis. Clin Microbiol Infect. 2012 Mar;18(3):260–7.

7. Shirai A, Dietel JW, Osterman JV. Indirect hemagglutination test for human antibody to typhus and spotted fever group rickettsiae. J Clin Microbiol. 1975 Nov;2(5):430–7.

8. Fujita H. Indirect hemagglutination test using polysaccharide antigen of spotted fever group rickettsia for the diagnosis of Japanese spotted fever. In: Kishimoto T, editor. The research on comprehensive prevention of Tick-Borne Bacterial Diseases focusing on rickettsia. MHLW grant research Report 201028024A [in Japanese]. Tokyo Japan: Ministry of Health, Labour and Welfare; 2011. p. 139–42.

medRxiv preprint doi: https://doi.org/10.1101/2022.10.16.22281137; this version posted October 17, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

9. Ormsbee R, Peacock M, Philip R, Casper E, Plorde J, Gabre-Kidan T, et al. Antigenic relationships between the typhus and spotted fever groups of rickettsiae. Am J Epidemiol. 1978 Jul;108(1):53–9.

medRxiv preprint doi: https://doi.org/10.1101/2022.10.16.22281137; this version posted October 17, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

[Type here]

Table. The antibody titers against *Rickettsia japonica* and *R. typhi* in patients exhibiting cross-reactions in IgG*

ID	Interval (Days)	*R. japonica*†		*R. typhi*‡	
		Acute	Convalescent	Acute	Convalescent
1002	10	160	5120	40	2560
1017	16	0	1280	0	40
1019	18	0	160	0	160
1027	22	0	2560	0	640
1029	7	80	1280	80	1280
1036	10	160	1280	0	40
1040	20	0	1280	0	1280
1048	16	40	2560	0	2560
1064	12	0	160	0	1280
1065	20	0	10240	40	20480
1066	15	0	5120	320	10240
1069	13	0	10240	0	40960
1071	14	40	640	0	160
1078	6	0	640	0	80
1082	13	0	2560	80	2560
1089	13	160	20480	640	40960
1094	4	40	2560	40	10240
1095	10	0	640	40	5120
1098	14	0	2560	0	5120
1106	13	0	1280	0	2560
1112	8	0	640	0	640
1113	27	0	80	0	80
1117	4	0	80	40	80
1126	17	640	2560	640	2560
1135	14	0	160	0	40
1148	9	0	1280	0	2560
1150	5	0	160	0	640

*The titer is expressed as the reciprocal of the highest dilution of the serum that demonstrated blue or blue black-colored rickettsial particles. (Reciprocals of titers. 0: <1:40)

† *R. japonica*, *Rickettsia japonica*

‡ *R. typhi*, *Rickettsia typhi*

medRxiv preprint doi: https://doi.org/10.1101/2022.10.16.22281137; this version posted October 17, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Figure. The cross-reactions against *Rickettsia typhi* in patients with Japanese spotted fever

(A) IgM (B) IgG

*JSF, Japanese spotted fever

Of the 145 cases analyzed, 119 underwent a ≥4-fold increase in titers against *R. japonica* or the occurrence of seroconversion in paired sera both for IgM and IgG, with 7 and 19 having these serological reactions only in IgM and IgG, respectively (total number of analyzed cases with IgM, 126; those with IgG, 138).

medRxiv preprint doi: https://doi.org/10.1101/2022.10.16.22281137; this version posted October 17, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Appendix

■ Indirect immunoperoxidase assay used in this study

The IP assays were implemented at Ohara Research Laboratory, Ohara General Hospital in Fukushima, and Mahara Institute of Medical Acarology in Tokushima.

The rickettsial strains were grown in L929 cells and used as antigens. The antigen was suspended in 0.01 M phosphate-buffered saline (PBS) with 0.3% bovine serum albumin fraction V at pH 7.2. The antigen was spotted on a slide, diluted to 100–200 rickettsial particles per field of a microscope (×40), air-dried for 30 min, and fixed in acetone for 10 min at room temperature. The slide-antigen was immediately utilized after drying, although it was maintained at −20 °C. Patient sera were diluted 2-fold in PBS, from 1:40 to 1:40960, and 0.01 mL of each dilution was placed on the antigen spot on the slide, incubated for 30 min at 36 °C in a humidified room, and washed twice in PBS for 5 min. Subsequently, each spot received 0.01 mL of 1:100 diluted peroxidase-conjugated antihuman IgG or IgM rabbit serum (γ-chain specific or μ-chain specific; DAKO Corp., Glostrup, Denmark), incubated for 30 min at 36 °C in the chamber, and rinsed as indicated above. Finally, the slide was placed in a freshly produced enzyme substrate solution comprising 1 volume of 80% ethanol containing 0.2% 4-Cl-1-naphthol, 4 volumes of PBS, and 0.01 volume of 3% peroxide for 5 min at room temperature. This was washed twice in distilled water for 5 min each time and then dried. The slide was then sealed with a coverslip and glycerol gelatin. A microscope was used to visually read the results. The titer was calculated as the reciprocal of the highest serum dilution that showed blue or blue-black rickettsial particles.

medRxiv preprint doi: https://doi.org/10.1101/2022.10.16.22281137; this version posted October 17, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Appendix Tables

Table 1. The antibody titers against *Rickettsia japonica* and *R. typhi* in patients with the cross-reactions in IgM*

ID	Interval (Days)	*R. japonica*†		*R. typhi*‡	
		Acute	Convalescent	Acute	Convalescent
1005	8	80	320	0	40
1007	14	0	1280	80	640
1017	16	0	160	0	40
1019	18	0	640	0	40
1020	10	0	320	0	160
1027	22	0	320	0	160
1033	15	0	320	0	40
1036	10	0	2560	0	80
1041	18	0	640	0	160
1044	14	0	10240	0	40
1048	16	0	640	0	40
1053	−	0	10240	0	40
1064	12	0	640	0	40
1069	13	0	160	0	40
1077	13	0	640	0	40
1078	6	0	160	0	40
1081	8	0	5120	0	80
1082	13	0	2560	0	160
1085	23	0	2560	0	40
1089	13	80	640	160	1280
1093	7	0	1280	0	80
1094	4	0	640	0	640
1096	7	0	320	0	160
1097	7	0	320	0	160
1118	13	0	640	0	80
1147	13	0	5120	0	80
1150	5	0	160	0	320

*The titer is expressed as the reciprocal of the highest dilution of the serum that demonstrated blue or blue black-colored rickettsial particles. (Reciprocals of titers, 0: <1:40) −, No data.

† *R. japonica*, *Rickettsia japonica*

‡ *R. typhi*, *Rickettsia typhi*

medRxiv preprint doi: https://doi.org/10.1101/2022.10.16.22281137; this version posted October 17, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Table 2. The antibody titers against *Rickettsia japonica* and *R. typhi* in patients with Japanese spotted fever confirmed using polymerase chain reaction or immunohistological tests*

(A)IgM

ID	Interval (Days)	*R. japonica*†		*R. typhi*‡	
		Acute	Convalescent	Acute	Convalescent
1018	29	0	160	0	0
1019	18	0	640	0	40
1023	21	0	640	0	0
1027	22	0	320	0	160
1031	12	0	1280	0	0
1037	15	0	160	0	0
1050	16	0	4960	0	0
1057	29	0	320	0	0
1070	15	0	640	0	0
1141	13	0	320	0	0
1142	10	0	320	0	0

(B)IgG

ID	Interval (Days)	*R. japonica*†		*R. typhi*‡	
		Acute	Convalescent	Acute	Convalescent
1018	29	0	320	0	0
1019	18	0	160	0	160
1023	21	0	320	0	0
1025	21	0	640	0	0
1027	22	0	2560	0	640
1031	12	0	640	0	0
1037	15	160	10240	0	0
1049	13	0	640	0	0
1050	16	0	2560	0	0
1057	29	0	640	0	0
1070	15	0	5120	0	0

*The titer is expressed as the reciprocal of the highest dilution of the serum that demonstrated blue or blue black-colored rickettsial particles. (Reciprocals of titers, 0: <1:40)

† *R. japonica*, *Rickettsia japonica*

‡ *R. typhi*, *Rickettsia typhi*

medRxiv preprint doi: https://doi.org/10.1101/2022.10.16.22281137; this version posted October 17, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Table 3. All the antibody titers against *Rickettsia japonica* and *R. typhi* in patients with Japanese spotted fever who exhibited cross-reactions*

		R. japonica†				*R. typhi*‡			
	Interval	Acute		Convalescent		Acute		Convalescent	
ID	(Days)	IgM	IgG	IgM	IgG	IgM	IgG	IgM	IgG
1002	10	0	160	160	5120	0	40	0	2560
1005	8	80	40	320	160	0	0	40	0
1007	14	0	0	1280	640	80	0	640	0
1017	16	0	0	160	1280	0	0	40	40
1019	18	0	0	640	160	0	0	40	160
1020	10	0	0	320	160	0	0	160	0
1027	22	0	0	320	2560	0	0	160	640
1029	7	0	80	640	1280	0	80	0	1280
1033	15	0	0	320	1280	0	0	40	0
1036	10	0	160	2560	1280	0	0	80	40
1040	20	0	0	40	1280	0	0	40	1280
1041	18	0	0	640	1280	0	0	160	0
1044	14	0	0	10240	2560	0	0	40	0
1048	16	0	40	640	2560	0	0	40	2560
1053	−	0	0	10240	40960	0	0	40	0
1064	12	0	0	640	160	0	0	40	1280
1065	20	0	0	0	10240	0	40	0	20480
1066	15	0	0	160	5120	0	320	0	10240
1069	13	0	0	160	10240	0	0	40	40960
1071	14	0	40	160	640	0	0	0	160
1077	13	0	0	640	1280	0	0	40	0
1078	6	0	0	160	640	0	0	40	80
1081	8	0	0	5120	1280	0	0	80	0
1082	13	0	0	2560	2560	0	80	160	2560
1085	23	0	0	2560	640	0	0	40	0
1089	13	80	160	640	20480	160	640	1280	40960
1093	7	0	0	1280	1280	0	0	80	0
1094	4	0	40	640	2560	0	40	640	10240
1095	10	0	0	640	640	0	40	0	5120
1096	7	0	0	320	1280	0	0	160	0
1097	7	0	0	320	640	0	0	160	0
1098	14	0	0	640	2560	0	0	0	5120
1106	13	0	0	0	1280	0	0	0	2560
1112	8	0	0	1280	640	0	0	0	640
1113	27	0	0	80	80	0	0	0	80
1117	4	0	0	0	80	0	40	0	80
1118	13	0	0	640	160	0	0	80	0
1126	17	0	640	0	2560	0	640	0	2560
1135	14	0	0	80	160	0	0	0	40
1147	13	0	0	5120	2560	0	0	80	0
1148	9	0	0	160	1280	0	0	0	2560
1150	5	0	0	160	160	0	0	320	640

*The titer is expressed as the reciprocal of the highest dilution of the serum that demonstrated blue or blue black-colored rickettsial particles. (Reciprocals of titers, 0: <1:40) −, No data.

† *R. japonica*, *Rickettsia japonica*

‡ *R. typhi*, *Rickettsia typhi*

medRxiv preprint doi: https://doi.org/10.1101/2022.10.16.22281137; this version posted October 17, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Although most cases were diagnosed with Japanese spotted fever (JSF) resulting from higher titers against *R. japonica* than those against *R. typhi* in IgM and/or IgG, some (whose ID is boldfaced) could not be identified as JSF, cross-reactions, or even murine typhus only by comparing each endpoint titer.

medRxiv preprint doi: https://doi.org/10.1101/2022.10.16.22281137; this version posted October 17, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Table 4. The antibody titers obtained using the indirect hemagglutination test against *Rickettsia japonica* and *R. typhi* in patients with Japanese spotted fever (JSF) who exhibited cross-reactions but whose disease could not be identified as JSF or Murine typhus based only on the result of the indirect immunoperoxidase assay*

*The titer is expressed as the reciprocal of the highest dilution of the serum that demonstrated blue or blue black-colored rickettsial particles. (Reciprocals of titers, 0: <1:40)

S, Standard assay; H, Highly sensitive assay; A, Assay after the absorption of hemagglutination antigens; −, No data.

† *R. japonica*, *Rickettsia japonica*

‡ *R. typhi*, *Rickettsia typhi*

		Indirect Immunoperoxidase assay								Indirect hemagglutination test											
		R. japonica†				*R. typhi*‡				*R. japonica*†						*R. typhi*‡					
	Interval	Acute		Convalescent		Acute		Convalescent		Acute			Convalescent			Acute			Convalescent		
ID	(Days)	IgM	IgG	IgM	IgG	IgM	IgG	IgM	IgG	S	H	A	S	H	A	S	H	A	S	H	A
1040	20	0	0	40	1280	0	0	40	1280	0	0	0	0	0	320	0	0	0	0	0	0
1065	20	0	0	0	10240	0	40	0	20480	0	160	–	160	2560	–	0	0	–	0	0	–
1089	13	80	160	640	20480	160	640	1280	40960	0	–	–	1280	–	–	0	–	–	0	–	–
1094	4	0	40	640	2560	0	40	640	10240	–	–	–	160	–	–	–	–	–	0	–	–
1106	13	0	0	0	1280	0	0	0	2560	–	–	–	–	1280	–	–	–	–	–	0	–
1117	4	0	0	0	80	0	40	0	80	–	–	–	–	–	–	–	–	–	–	–	–
1126	17	0	640	0	2560	0	640	0	2560	0	0	–	0	640	–	0	0	–	0	0	–
1150	5	0	0	160	160	0	0	320	640	0	0	–	160	1280	640	0	0	–	160	640	640

medRxiv preprint doi: https://doi.org/10.1101/2022.10.16.22281137; this version posted October 17, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

medRxiv preprint doi: https://doi.org/10.1101/2022.10.16.22281137; this version posted October 17, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Appendix Figure

Figure. The change in titers for *Rickettsia japonica* and *R. typhi* between acute and convalescent sera*

*The titer is expressed as the reciprocal of the highest dilution of the serum that demonstrated blue or blue black-colored rickettsial particles.

† *R. japonica, Rickettsia japonica*

‡ *R. typhi, Rickettsia typhi*


(A)
Positive cross-reaction
27
(21.4%)
JSF* satisfying
serologic criteria
126
Negative cross-reaction
99
(78.6%)
(B)
Positive cross-reaction
27
(19.6%)
JSF* satisfying
serologic criteria
138
Negative cross-reaction
111
(80.4%)


R. japonica† IgM
R. japonica† IgG
R. typhi‡ IgM
R. typhi‡ IgG
40960≥
20480
10240
5120
2560
1280
640
320
160
80
40
<40
Acute
Convalescent